Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03839498 · ClinicalTrials.gov registry record · Phase 2
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
A Phase 2 study of Pheochromocytoma and Paraganglioma, sponsored by Columbia University.
- Active
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT03839498: Active Phase 2 study of Pheochromocytoma and Paraganglioma, sponsored by Columbia University.
NCT03839498 is a Phase 2 study of Pheochromocytoma and Paraganglioma that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 6 participants, below the 519-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03839498, a Phase 2 study of Pheochromocytoma and Paraganglioma, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objective: To determine the response rate (RR) of metastatic or locally advanced pheochromocytoma/paraganglioma to axitinib administered daily. Secondary Objectives: * Determine the progression-free survival. * In an exploratory manner examine the extent of activation of the VEGFR pathway in pheochromocytoma/paraganglioma using a semi-quantitative immunohistochemistry assay and examine the relationship with response to therapy. * Perform pharmacogenomics analyses of drug metabolism and transport proteins through germline DNA examination.
Primary Outcome
This study is designed to determine the percentage of patients whose cancer shrinks or disappears after treatment.
Conditions Studied
Interventions
- DRUG Axitinib
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-01-22 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What the registry record for NCT03839498 still lists
NCT03839498 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 519-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Pheochromocytoma appearing as the primary indexed condition, and to 1 intervention - of which Axitinib is the first listed.
NCT03839498 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03839498 about?
NCT03839498 is a clinical study titled "Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma". Primary Objective: To determine the response rate (RR) of metastatic or locally advanced pheochromocytoma/paraganglioma to axitinib administered daily. Secondary Objectives: * Determine the progression-free survival. * In an exploratory manner examine the extent of activation of the VEGFR pathway...
What is the current status of trial NCT03839498?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-01-22. Estimated completion is 2027-02.
What conditions does trial NCT03839498 study?
This clinical trial studies the following conditions: Pheochromocytoma, Paraganglioma.
What interventions are being tested in trial NCT03839498?
The interventions under investigation include: Axitinib (DRUG).
Who is sponsoring clinical trial NCT03839498?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03839498 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pheochromocytoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03839498's enrollment target sits among peer trials
6 15th of 14 the lowest of 14 other Pheochromocytoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pheochromocytoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
ACTIVE NOT RECRUITING · Phase 2
-
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
ACTIVE NOT RECRUITING · Phase 2
-
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
COMPLETED · Phase 2
-
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI